People living with scleroderma face unique challenges. For some, those challenges include developing pulmonary arterial hypertension (PAH)—a progressive and life-threatening condition. Timely diagnosis and access to new treatments can make all the difference, but too often, patients face delays that can cost them their health and quality of life.

In August 2024, Health Canada approved sotatercept (Winrevair), a breakthrough treatment that offers hope to PAH patients, including those in our scleroderma community. Canada’s Drug Agency has now recommended that sotatercept be publicly funded. For this treatment to become accessible to patients, the pan-Canadian Pharmaceutical Alliance (pCPA) must negotiate pricing and funding with the manufacturer on behalf of the provincial drug programs.

That’s why we’re proud to support PHA Canada’s Time Matters PAH campaign—an advocacy initiative pushing for timely access to sotatercept, a breakthrough treatment that offers hope to PAH patients, including those in our scleroderma community.

Here’s how you can help—and it’s simple:
✅ Take 2 minutes to send a pre-written letter to your provincial health minister.
✅ Share this with your family and friends to amplify your impact.

Every voice matters.

By speaking up, you are helping pulmonary arterial hypertension (PAH) patients access this new treatment.

Take action now ➡️ www.phacanada.ca/advocate

Together, we can ensure timely access to life-changing treatment for PAH patients in Canada.

The Scleroderma Association of B.C.